key: cord-0733820-xrjh2zan
authors: Benucci, Maurizio; Giannasi, Gianfranco; Cecchini, Paolo; Gobbi, Francesca Li; Damiani, Arianna; Grossi, Valentina; Infantino, Maria; Manfredi, Mariangela
title: COVID‐19 pneumonia treated with Sarilumab: A clinical series of eight patients
date: 2020-06-16
journal: J Med Virol
DOI: 10.1002/jmv.26062
sha: 68d0941328067c626c7e519ab72dfc7b605252f9
doc_id: 733820
cord_uid: xrjh2zan

The development of cytokine release syndrome and T cell abnormalities plays a key role in the progression of Coronavirus disease in 2019 (COVID-19). Under these circumstances, persistent viral stimulation leads to a significant increase in circulating cytokines such as interleukin (IL) -6, IL-10 and TNF-α. We describe a clinical series of eight patients treated with Sarilumab an IL-6R inhibitor administered early in Covid-19 pneumonia. This article is protected by copyright. All rights reserved.

To the Editor,

We read with interest the work by Luo et al, 1 Table 1 shows the variation of the parameters, both laboratory and functional, in our clinical series of the eight treated patients. Seven of them showed an improvement of the Horovitz index and a progressive reduction in the echo score (Figures 1 and 2 ).

In these patients, aggressive and early treatment with an IL-6 inhibitor led to discharge within 14 days of hospitalization and seven out of eight patients resulted negative at the molecular test.

An 83-year-old patient had no improvement in Horovitz's functional index or echo score and died 13 days after hospitalization. There is also a progressive reduction in the SAA and CRP inflammation parameters. In RA, the determination of early synovitis may predict erosive damage over time 6 and the treat-to-target strategy is capable of determining clinical remission and blockage of radiological damage. 7 In this context, timing is even more fundamental. Hence, the rheumatologic concept of a window of opportunity in treating RA can be translated into therapeutic strategies for dealing with the COVID-19 pandemic. T0   lymphocyte  cells/mcL  T1  T2   T0  SAA mg/L  T1  T2   T0  IL-6 pg/mL  T1  T2   T0  CRP mg/dL  T1  T2   560  590  630  961  54  15, 6  86  >200  >200  22  6, 5  2, 3   480  459  638  846  708  17, 3  68  >200  >200  36, 1  9, 

Tocilizumab treatment in COVID-19: a single center experience

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Off-label use of Tocilizumab in patients with SARS-CoV-2 Infection

Effective Treatment of Severe COVID-19 Patients with Tocilizumab

Proposal for international standardization of the use of lung ultrasound for patients with COVID-19: a simple, quantitative, reproducible method

Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update